Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of fluid and electrolyte depletion,Provision of caloric intake in patients requiring parenteral nutrition,Correction of hypoglycemia,Maintenance fluid therapy
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: <15 minutes due to rapid cellular uptake and metabolism; sodium and chloride: no defined half-life as electrolytes are homeostatically regulated.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is rapidly metabolized via glycolysis and the Krebs cycle; sodium chloride is not metabolized but excreted renally.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal; dextrose is metabolized to CO2 and water; sodium and chloride are excreted renally with >90% reabsorption under normal conditions.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible; sodium and chloride: not protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: approximately 0.2 L/kg (total body water); sodium and chloride: distribute into extracellular fluid (approx 0.2 L/kg).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
100% for intravenous route; not applicable for oral/other routes.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific dose adjustment for dextrose; monitor fluid and electrolyte balance. In severe renal impairment (e GFR <30 m L/min/1.73 m²), restrict volume as needed to avoid fluid overload and hyperkalemia when combined with sodium chloride.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment for Child-Pugh class; monitor glucose and fluid status. Caution in severe hepatic failure due to risk of hyperglycemia and fluid retention.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Weight-based dosing: Intravenous infusion at 4-8 mg/kg/min for glucose provision; typical maintenance fluid rates: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for each additional kg. Individualize based on age, weight, and clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Monitor for fluid overload, hyperglycemia, and electrolyte disturbances. Use lower initial infusion rates (e.g., 50-100 m L/hour) and adjust based on renal function and cardiovascular status. Avoid excessive sodium load in patients with hypertension or heart failure.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Not for use in patients with intracranial or intraspinal hemorrhage, or in those with known hypersensitivity to corn or corn products (dextrose source).
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hyperglycemia, especially in diabetic patients,Risk of fluid overload, especially in patients with renal impairment or heart failure,Electrolyte imbalances (e.g., hypernatremia, hyperchloremia) with excessive administration,Use with caution in patients with hepatic disease, as dextrose may exacerbate encephalopathy
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperglycemia,Hypernatremia,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe hypokalemia (can worsen with dextrose infusion)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, as this solution provides dextrose (sugar) and sodium, patients with diabetes or salt-restricted diets should be monitored. Avoid concurrent intake of high-sugar or high-salt foods without medical advice.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglycemia-related congenital anomalies. Intravenous administration may be necessary in third trimester for fluid maintenance. No direct fetal toxicity.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose and sodium chloride are normal constituents of breast milk. Intravenous infusion does not alter milk composition significantly. M/P ratio not applicable. Considered compatible with breastfeeding.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dosing adjustment required solely for pregnancy. However, increased plasma volume in pregnancy may require careful monitoring of fluid balance to avoid overload. Adjust rate and volume based on clinical status, not pregnancy per se.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Use with caution in patients with congestive heart failure, renal impairment, or conditions causing sodium retention. Monitor serum glucose and electrolytes, especially in diabetic patients or those receiving parenteral nutrition. Avoid in patients with hyperglycemia, hyponatremia, or fluid overload. Do not administer simultaneously with blood products due to risk of hemolysis. Inspect for particulate matter and discoloration before use; discard if present.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Inform your healthcare provider if you have diabetes, high blood pressure, heart or kidney disease, or fluid retention.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing.,Tell your doctor if you experience headache, confusion, muscle cramps, or swelling of hands/ankles.,This solution provides sugar and salt; discuss any dietary restrictions with your doctor.,Do not use the solution if it is cloudy, discolored, or contains particles.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglyc. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.